Lahore: Ferozsons Laboratories Limited has reported an increase in its net revenue for the fiscal year ending June 30, 2026, reflecting a robust performance despite rising costs and financial challenges. The pharmaceutical company announced its financial results on September 29, 2026, detailing key metrics from its unconsolidated statement of profit or loss.

The company achieved a net revenue of ?15.76 billion, up from ?13.86 billion in the previous year, marking a very large or significant move. This increase underscores the company's capacity to expand its market reach and enhance its sales performance over the fiscal year.

However, the cost of sales also rose, reaching ?9.13 billion from ?8.14 billion the previous year, indicating increased operational expenses. Consequently, the gross profit stood at ?6.63 billion, compared to ?5.72 billion in 2025.

Administrative expenses amounted to ?930.40 million, and selling and distribution expenses were reported at ?4.26 billion. Other expenses slightly decreased to ?115.26 million.

According to information available from the Pakistan Stock Exchange (PSX), Ferozsons Laboratories recorded a profit from operations of ?1.39 billion, a moderate move from the previous year's ?1.38 billion. The finance cost experienced a reduction to ?318.51 million from ?452.82 million, contributing to the overall profitability of the company.

The profit before income tax climbed to ?1.04 billion from ?896.50 million, leading to a profit after taxation of ?650.90 million, up from ?528.24 million in 2025, which is classified as a big move. The earnings per share improved to ?14.97 from ?12.15.

In terms of cash flow, the company reported a net cash generation from operating activities at ?574.92 million, down from the previous year's ?1.15 billion. The cash flow from investing activities resulted in a net outflow of ?137.82 million, while financing activities led to a net cash outflow of ?617.01 million.

Despite these challenges, Ferozsons Laboratories continues to demonstrate resilience in the face of financial headwinds, underscoring its position in the designated market category of the pharmaceutical sector.